Background: Sudden cardiac death is common in patients on hemodialysis (HD), and its rate is as high as 25% of all cardiac deaths associated with left ventricular hypertrophy (LVH) and secondary hyperparathyroidism. A prolonged QT interval on standard electrocardiography is related to an increase in sudden death in various patient groups. It is also well known that LVH has been noted in uremic patients with high parathyroid hormone levels. Methods: To evaluate the response of intravenous calcitriol treatment on the QT interval and LVH in HD patients with secondary hyperparathyroidism (intact parathyroid hormone, iPTH, >450 ng/ml), echocardiographic, electrocardiographic (ECG), and biochemical assessments were performed over a 15-week period in 25 HD patients before and after intravenous calcitriol treatment. We also evaluated 25 age-, sex-, HD duration-, and BMI-matched HD control patients with secondary hyperparathyroidism. Results: In patients receiving intravenous calcitriol, a significant reduction in iPTH levels (p < 0.05) and alkaline phosphatase levels (p < 0.01) was found without changes in values of serum calcium and ionized Ca2+, phosphorus, Na+, K+, Mg2+, hematocrit, blood pressure, or other hemodynamic changes. Echocardiograms showed significant decreases in the thickness of the interventricular septum (p < 0.05), left posterior wall thickness (p < 0.05), and left ventricle mass index (LVMi, p < 0.01). In addition, sequential ECG measurement in patients with calcitriol treatment showed significant reductions in QTcmax (QTmax interval corrected for heart rates, p < 0.01) and QTc dispersion (QT dispersion corrected for heart rates, p < 0.01). However, in the control patients, biochemical, hemodynamic, and ECG changes, as well as myocardial structural and functional changes were not seen. Multiple regression analysis in all patients indicated that iPTH and LVMi levels were independent predictors of QTcmax while the LVMi level was the only independent predictor of QTc dispersion (p < 0.05). Conclusions: Our study showed a significant correlation between LVMi and QT dispersion in HD patients with secondary hyperparathyroidism. Intravenous calcitriol treatment, to be used for the control of secondary hyperparathyroidism, was found to cause regression of myocardial hypertrophy and a reduction in the QTc interval and dispersion, without biochemical and hemodynamic changes. These findings suggest that an active vitamin D metabolite has a cardioprotective action in HD patients.

Keywords:
Calcitriol, Myocardial hypertrophy, QT dispersion, Secondary hyperparathyroidism
1.
Multicentre, cross-sectional study of ventricular arrhythmias in chronically haemodialysed patients. Gruppo Emodialisi e Patologie Cardiovasculari. Lancet 1988;ii:305–308.
2.
Chazan JA: Sudden death in patients with chronic renal failure on hemodialysis. Nephrol Dial Transplant 1987;16:447–448.
3.
Abe S, Yoshizawa M, Nakanishi N, et al: Electrocardiographic abnormalities in patients receiving hemodialysis. Am Heart J 1996;131:1137–1144.
4.
Lorincz I, Zilabi Z, Kun C, et al: ECG abnormalities in hemodialysis (letter). Am Heart J 1997;134:1138–1140.
5.
Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO4, Ca × PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131–2138.
6.
Schouten EG, Dekker JM, Meppelink P, Kok FJ, Vandenbroucke JP, Pool J: QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. Circulation 1991;84:1516–1523.
7.
Beaubien ER, Pylypchuk GB, Akhtar J, Biem HJ: Value of corrected QT interval dispersion in identifying patients initiating dialysis at increased risk of total and cardiovascular mortality. Am J Kidney Dis 2002;39:834–842.
8.
Naas AA, Davidson NC, Thompson C, et al: QT and QTc dispersion are accurate predictors of cardiac death in newly diagnosed non-insulin dependent diabetes: cohort study. BMJ 1998;316:745–746.
9.
Yi G, Crook R, Guo XH, et al: Exercise-induced changes in the QT interval duration and dispersion in patients with sudden cardiac death after myocardial infarction. Int J Cardiol 1998;63:271–279.
10.
Kannel WB: Left ventricular hypertrophy as a risk factor in arterial hypertension. Eur Heart J 1992;13(suppl D):82–88.
11.
Davey PP, Bateman J, Mulligan IP, Forfar C, Barlow C, Hart G: QT interval dispersion in chronic heart failure and left ventricular hypertrophy: relation to autonomic nervous system and Holter tape abnormalities. Br Heart J 1994;71:268–273.
12.
Glancy JM, Garratt CJ, Woods KL, de Bono DP: QT dispersion and mortality after myocardial infarction. Lancet 1995;15:945–948.
13.
Barr CS, Naas AA, Fenwick M, Struthers AD: Enalapril reduces QTc dispersion in mild congestive heart failure secondary to coronary heart disease. Am J Cardiol 1997;79:328–333.
14.
Lim PO, Nys M, Naas AA, Struthers AD, Osbakken M, MacDonald TM: Irbesartan reduces QT dispersion in hypertensive individuals. Hypertension 1999;33:713–718.
15.
London GM, de Vemejoul M-C, Fabiani F, et al: Secondary hyperthyroidism and cardiac hypertrophy in hemodialysis patients. Kidney Int 1987;32:900–907.
16.
Amann K, Ritz E, Wiest G, et al: A role of parathyroid hormone for activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 1994;4:1814–1819.
17.
Park CW, Oh YS, Shin YS, et al: Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999;33:73–81.
18.
Qi Q, Monier-Faugere MC, Geng Z, Malluche HH: Predictable value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995;26:622–631.
19.
Shan DJ, De Mora A, Kisslo J, Weyman A: Recommendation regarding quantitation in M-mode echocardiography: result of a survey of echo measurement. Circulation 1978;70:425–431.
20.
Lewis JF, Kuo LC, Nelson JC, et al: Pulsed Doppler echocardiographic determination of stroke volume and cardiac output: clinical validation of two new methods using the apical window. Circulation 1984;70:425–431.
21.
Devereux RB, Koren MJ, Simone G, et al: Methods of detection of LVH: application to hypertensive heart disease. Eur Heart J 1993;14(suppl D):8–15.
22.
Clarkson PBM, Naas AAO, McMahon A, et al: QT dispersion in essential hypertension. QJM 1995;88:327–332.
23.
Weber KT, Pick R, Silver MA, et al: Fibrillar collagen and remodeling of dilated canine left ventricle. Circulation 1990;82:1387–1401.
24.
Morris ST, Galiatsou E, Stewart GA, et al: QT dispersion before and after hemodialysis. J Am Soc Nephrol 1999;10:160–193.
25.
Weber KT, Brilla CG, Janieki JS: Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993;27:341–348.
26.
Kirvela M, Yli-Hankala A, Lindgren L: QT dispersion and autonomic function in diabetic and nondiabetic patients with renal failure. Br J Anaesth 1994;73:801–804.
27.
Grafter U, Battler A, Eldar M, et al: Effect of hyperparathyroidism on cardiac function in patients with end-stage renal disease. Nephron 1985;41:31–33.
28.
Katoh Y, Klein KL, Kaplan RA, et al: Parathyroid hormone has a positive inotropic action in the rat. Endocrinology 1981;109:2252–2254.
29.
Drueke T, Faucher M, Fleury J, et al: Effect of parathyroidectomy on left ventricular function in hemodialysis patients. Lancet 1987;i:112–114.
30.
Li YC, Kong J, Wei M, et al: 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002;110:229–238.
31.
Simpson RU, Gregory AT, Alison JA: Identification of 1,25-dihydroxyvitamin D3 receptors and activates in muscle. J Biol Chem 1985;260:8882–8886.
32.
Thomasset M, Parkes CO, Cuisinier-Gleizes P: Rat calcium-binding proteins: distribution, development, and vitamin D dependence. Am J Physiol 1982;243:E483–E488.
33.
Teng M, Wolf M, Ofsthun MN, et al: Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 2005;16:1115–1125.
34.
Walters MR, Ilenchuk TT, Claycomb WC: 1,25-Dihydroxyvitamin D3 stimulates 45Ca2+ uptake by cultured adult rat ventricular muscle cells. J Biol Chem 1987;262:2536–2541.
35.
Dean JW, Lab MJ: Regional changes in ventricular excitability during load manipulation of the in situ pig heart. J Physiol 1990;429:387–400.
36.
Llach F, Hervas J, Cerezo S: The importance of dosing intravenous calcitriol in dialysis patients with severe hyperparathyroidism. Am J Kidney Dis 1995;26:845–851.
37.
Spraque S, Moe SM: Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am J Kidney Dis 1992;19:532–539.
38.
Ritz E, Matthias S, Seidel A, et al: Disturbed calcium metabolism in renal failure – pathogenesis and therapeutic strategies. Kidney Int Suppl 1992;42:S37–S42.
© 2006 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.